Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

a milestone payment from Johnson &

Johnson Pharmaceutical Research and Development, LLC (J&JPRD) triggered

by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as

a development candidate emerging from a collaboration with Sunesis.

-- Lesley A. Stolz, Ph.D., joined Sunesis in November 2007 as Vice

President, Corporate and Business Development.

Financial Highlights

-- Revenue totaled $2.0 million and $9.7 million, respectively, for the

three months and year ended December 31, 2007, compared to $2.0 million

and $13.7 million for the three months and year ended December 31,

2006. The decrease in revenue year-over-year was primarily due to

lower milestone payments from Merck & Co., Inc. in 2007 compared to

2006.

-- Research and development (R&D) expense was $8.3 million for the fourth

quarter of 2007, compared to $8.5 million for the same period in 2006.

R&D expense for the year ended December 31, 2007 totaled $36.1 million,

compared to $35.6 million in 2006. The year-over-year increase in R&D

expense was primarily due to increased clinical trial activity for SNS-

595 and preclinical program costs, partially offset by lower headcount

and lower R&D expense associated with SNS-032 and SNS-314 due to

reduced research activities in these programs.

-- General and administrative (G&A) expense for the fourth quarter of 2007

was $2.8 million, compared to $3.4 million for the fourth quarter of

2006. For the year ended December 31, 2007, G&A expense was $13.6

million, compared to $12.3 million in 2006. The quarter-over-quarter

decrease primarily resulted from lower professional services expense in

2007 compared to 2006. The year-over-year increase in G&A expense was

primarily due to increased non-cash stock-based compensation expense,
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Bermuda , Sept. 2, 2015 Axovant Sciences ... the treatment of dementia, today announced upcoming presentations at three ... PM at the Baird 2015 Healthcare Conference in ... , Thursday, September 10 at 2:00 PM at the ... at the Millennium Broadway Hotel & Conference Center , ...
(Date:9/2/2015)... ... 02, 2015 , ... The wet form of macular degeneration, ... endothelial growth factor agents given by injection into the eye. Dry macular degeneration ... protocol for the many millions diagnosed with it. AMD usually starts in older ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly are adopting ... Research reveals in its new report that the U.S. will generate the greatest ... generates the most market demand. , BCC Research examines plant-derived drugs in ...
(Date:9/2/2015)... 2, 2015 BioLight Life ... the "Company"), a firm that invests in, manages ... diagnostics, announced today that presentations highlighting its IOPtiMate™ ... delivered at the Ophthalmology Futures European Forum and ... Cataract & Refractive Surgeons ("ESCRS"), both taking place ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... GLENWOOD, Ill., Aug. 29 Landauer, Inc. ... environmental radiation,monitoring, today announced the appointment of ... of Directors., Mr. Leatherman, currently an ... global contract negotiations, was,previously the Chief Financial ...
... Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... obesity, today announced,that the Company will be presenting at ... the Biotech Industry Thursday, September 4, 2008, 10:00 ... UBS Global Life Sciences Conference Tuesday, September ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... approval from the U.S. Food & Drug Administration,(FDA) ... Ortho McNeil Janssen,s,Razadyne(R) (galantamine hydrobromide), 4 mg, 8 ... its generic Razadyne tablets product immediately., Barr ...
Cached Biology Technology:Landauer, Inc. Appoints Two New Members to Board of Directors 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
(Date:8/5/2015)... , August 5, 2015 Transparency ... "Facial Recognition Market - Global Industry Analysis, Size, Share, ... market for facial recognition is forecast to reach US$ ... increased demand for surveillance systems by civil and government ... of crimes and terrorist activities across the globe that ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... discovery by scientists from the Mayo Clinic in Jacksonville, ... Disease that actually removes amyloid plaquesconsidered a hallmark of ... The FASEB Journal ( http://www.fasebj.org ), is ... immune cells (microglia) are activated by the interleukin-6 protein ...
... sequence was published in 2001, scientists have been working to figure ... a desert and finding a large book in a language you ... saying. "In the case of the human genome, the ... But we don,t yet understand its language," said Morgan Giddings, Ph.D., ...
... the Oct. 15 issue of the Journal of Clinical ... exercise program may benefit obese patients with mild to moderate ... condition. Results show improvement in typical OSA symptoms ... and mood after the completion of a 16-week diet and ...
Cached Biology News:Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease 2UNC scientists win $1.6 million stimulus award to accelerate decoding of human genome 2Improved diet and exercise alone unlikely to cure obstructive sleep apnea in obese patients 2
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Complete cell culture media with cytokines...
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
Biology Products: